Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14543829 | 0.87 | TDP1 (0.57) | ALDH1A1MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL11104956 | 0.84 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL7906540 | 0.83 | MEN1 (0.50) | ALDH1A1MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL2507796 | 0.80 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL28902155 | 0.79 | TSHR (0.52) | ALDH1A1MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL28570809 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL28477161 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL7539076 | 0.78 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL21222945 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL11100777 | 0.77 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111205301-B | Furan [2,3-c ] chromene derivatives and process for preparing the same | 安徽师范大学 | 2023-02-21 | — | — | CN | disclosed |
| CN-111205301-A | Furo [2,3-c ] chromene derivative and preparation method thereof | 安徽师范大学 | 2020-05-29 | — | — | CN | disclosed |
| US-9701684-B2 | Chiral fluorinating reagents | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-9701684-B2 | Chiral fluorinating reagents | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-20150284401-A1 | CHIRAL FLUORINATING REAGENTS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2015-10-08 | — | — | US | disclosed |
| US-20150284401-A1 | CHIRAL FLUORINATING REAGENTS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2015-10-08 | — | — | US | disclosed |
| WO-2014068341-A2 | CHIRAL FLUORINATING REAGENTS | ISIS INNOVATION LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
| US-20110172244-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-07-14 | — | — | US | disclosed |
| EP-2252586-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-11-24 | — | — | EP | disclosed |
| EP-2161266-A1 | Benzofuran derivatives as orexin receptor antagonists | EVOTEC Neurosciences GmbH (DE) | 2010-03-10 | — | — | EP | disclosed |
| WO-2009105722-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
| US-6194590-B1 | PREPARING SUBSTITUTED BENZOFURAN-3-ONES BY REACTING SALICYLIC ACID ETHER COMPOUND WITH STRONG BASE IN INERT GAS AND/OR IN PRESENCE OF DILUENT; REACTING BENZOFURANONECARBOXYIC ACID ESTER WITH POTASSIUM HYDROXIDE AND THEN ACID ACID | BAYER AKTIENGESELLSCHAFT (DE) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284401-A1 | CHIRAL FLUORINATING REAGENTS | TIAM1, AFF2, AFF1 | ALDH1A1 800/4885MEN1 1062/4885KMT2A 3049/4885 |
| US-20110172244-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | ALDH1A1 1627/4885MEN1 2874/4885KMT2A 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.